Supplementary Table 6. Baseline demographic and clinical characteristics of the study population in the longitudinal analysis of serum agrin-positive exosomes (n=44).

Cohort	PDAC
characteristics	(n/%)
Sex	00 (50.4)
Male	26 (59.1)
Female	18 (40.9)
Age, years (mean±SD)	70.0 ± 8.6
Stage	4 (0.4)
IA	4 (9.1)
IB	4 (9.1)
IIA 	1 (2.3)
IIB	9 (20.5)
	9 (20.5)
IV	17 (38.6)
Surgery Stage	19 (43.2)
IA	3 (15.8)
IB	2 (10.5)
IIA	1 (5.3)
IIB	7 (36.8)
III	5 (26.3)
IV	1 (5.3)
Chemotherapy	21 (47.7)
Folfirinox-based	12 (27.3)*
regimens	
Stage	
IA	1 (8.3)
IB	1 (8.3)
IIA	0 (0)
IIB	3 (25.0)
III	2 (16.7)
IV	5 (41.7)
Non-folfirinox-based	11 (25.0)*
regimens	
Stage	
IA	0 (0)
IB	1 (9.1)
IIA	0 (0)
IIB	3 (27.3)
III	4 (36.4)
IV	3 (27.3)

PDAC – Pancreatic Ductal Adenocarcinoma; SD – Standard Deviation \*2 patients included in this cohort were submitted to folfirinox and non-folfirinox-based regimens